Logo image of SRTA

STRATA CRITICAL MEDICAL INC (SRTA) Stock Fundamental Analysis

USA - NASDAQ:SRTA - US0926671043 - Common Stock

5.24 USD
+0.14 (+2.75%)
Last: 9/26/2025, 2:52:54 PM
Fundamental Rating

3

Overall SRTA gets a fundamental rating of 3 out of 10. We evaluated SRTA against 0 industry peers in the Unkown industry. The financial health of SRTA is average, but there are quite some concerns on its profitability. SRTA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SRTA has reported negative net income.
SRTA had a positive operating cash flow in the past year.
In the past 5 years SRTA always reported negative net income.
SRTA had a negative operating cash flow in each of the past 5 years.
SRTA Yearly Net Income VS EBIT VS OCF VS FCFSRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA -7.36%
ROE -8.51%
ROIC N/A
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
SRTA Yearly ROA, ROE, ROICSRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

In the last couple of years the Gross Margin of SRTA has grown nicely.
SRTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
SRTA Yearly Profit, Operating, Gross MarginsSRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, SRTA has more shares outstanding
SRTA has more shares outstanding than it did 5 years ago.
SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRTA Yearly Shares OutstandingSRTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRTA Yearly Total Debt VS Total AssetsSRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SRTA has an Altman-Z score of 7.04. This indicates that SRTA is financially healthy and has little risk of bankruptcy at the moment.
SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.04
ROIC/WACCN/A
WACCN/A
SRTA Yearly LT Debt VS Equity VS FCFSRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

SRTA has a Current Ratio of 5.95. This indicates that SRTA is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 5.95 indicates that SRTA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.95
Quick Ratio 5.95
SRTA Yearly Current Assets VS Current LiabilitesSRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

SRTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.12%, which is quite impressive.
SRTA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.70%.
The Revenue has been growing by 70.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)62.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)6.7%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%4.2%

3.2 Future

Based on estimates for the next years, SRTA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.23% on average per year.
The Revenue is expected to grow by 7.57% on average over the next years.
EPS Next Y64.16%
EPS Next 2Y27.05%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue Next Year7.33%
Revenue Next 2Y7.13%
Revenue Next 3Y7.57%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRTA Yearly Revenue VS EstimatesSRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
SRTA Yearly EPS VS EstimatesSRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRTA Price Earnings VS Forward Price EarningsSRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRTA Per share dataSRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as SRTA's earnings are expected to grow with 24.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.05%
EPS Next 3Y24.23%

More info and screens

0

5. Dividend

5.1 Amount

SRTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA CRITICAL MEDICAL INC

NASDAQ:SRTA (9/26/2025, 2:52:54 PM)

5.24

+0.14 (+2.75%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-10 2025-11-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change-0.13%
Market Cap0
Analysts84
Price Target8.5 (62.21%)
Short Float %N/A
Short Ratio3.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.79%
Min EPS beat(2)-11.41%
Max EPS beat(2)64.99%
EPS beat(4)2
Avg EPS beat(4)16.68%
Min EPS beat(4)-24.95%
Max EPS beat(4)64.99%
EPS beat(8)4
Avg EPS beat(8)-21.68%
EPS beat(12)6
Avg EPS beat(12)-13.54%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.01%
Min Revenue beat(2)7.7%
Max Revenue beat(2)8.32%
Revenue beat(4)3
Avg Revenue beat(4)4.72%
Min Revenue beat(4)-1.39%
Max Revenue beat(4)8.32%
Revenue beat(8)6
Avg Revenue beat(8)3.41%
Revenue beat(12)10
Avg Revenue beat(12)5.68%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.6
P/FCF N/A
P/OCF 314.07
P/B 1.82
P/tB 2.46
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)0.02
OCFY0.32%
SpS3.28
BVpS2.88
TBVpS2.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.36%
ROE -8.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.01%
FCFM N/A
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
F-Score6
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 331.71%
Cap/Sales 8.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.95
Quick Ratio 5.95
Altman-Z 7.04
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)198.6%
Cap/Depr(5y)143.5%
Cap/Sales(3y)4.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y64.16%
EPS Next 2Y27.05%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue 1Y (TTM)6.7%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%4.2%
Revenue Next Year7.33%
Revenue Next 2Y7.13%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
EBIT growth 1Y62.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.57%
EBIT Next 3Y41.77%
EBIT Next 5YN/A
FCF growth 1Y53.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.19%
OCF growth 3YN/A
OCF growth 5YN/A